UY38511A - Terapia de combinación cd70 - Google Patents
Terapia de combinación cd70Info
- Publication number
- UY38511A UY38511A UY0001038511A UY38511A UY38511A UY 38511 A UY38511 A UY 38511A UY 0001038511 A UY0001038511 A UY 0001038511A UY 38511 A UY38511 A UY 38511A UY 38511 A UY38511 A UY 38511A
- Authority
- UY
- Uruguay
- Prior art keywords
- combination therapies
- combination therapy
- treatment
- aml
- bcl
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title abstract 5
- 102100025221 CD70 antigen Human genes 0.000 title abstract 2
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 title abstract 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 abstract 1
- 239000012664 BCL-2-inhibitor Substances 0.000 abstract 1
- 229940123711 Bcl2 inhibitor Drugs 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 201000000050 myeloid neoplasm Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 abstract 1
- 229960001183 venetoclax Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La invención se refiere a terapias de combinación, particularmente a terapias de combinación para el tratamiento de neoplasias malignas mieloides. Las terapias de combinación son particularmente útiles en métodos para el tratamiento de leucemia mieloide aguda (LMA). Las terapias de combinación incluyen un anticuerpo o fragmento de unión al antígeno de este que se une a CD70 y un inhibidor de BCL-2, preferentemente venetoclax o una sal farmacéuticamente aceptable de estos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1820582.3A GB201820582D0 (en) | 2018-12-18 | 2018-12-18 | CD70 combination therapy |
GBGB1911007.1A GB201911007D0 (en) | 2019-08-01 | 2019-08-01 | CD70 combination therapy |
GBGB1917701.3A GB201917701D0 (en) | 2019-12-04 | 2019-12-04 | CD70 Combination therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
UY38511A true UY38511A (es) | 2020-07-31 |
Family
ID=69104399
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001038511A UY38511A (es) | 2018-12-18 | 2019-12-17 | Terapia de combinación cd70 |
Country Status (20)
Country | Link |
---|---|
US (2) | US11712468B2 (es) |
EP (2) | EP3890740B1 (es) |
JP (1) | JP2022515077A (es) |
KR (1) | KR20210106428A (es) |
CN (2) | CN115920034A (es) |
AU (1) | AU2019409936A1 (es) |
BR (1) | BR112021011684A2 (es) |
CA (1) | CA3117282A1 (es) |
DK (1) | DK3890740T3 (es) |
ES (1) | ES2941638T3 (es) |
FI (1) | FI3890740T3 (es) |
HU (1) | HUE061710T2 (es) |
IL (1) | IL284015B1 (es) |
LT (1) | LT3890740T (es) |
MX (1) | MX2021007350A (es) |
PL (1) | PL3890740T3 (es) |
PT (1) | PT3890740T (es) |
SG (1) | SG11202105197UA (es) |
UY (1) | UY38511A (es) |
WO (1) | WO2020127503A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UY38511A (es) | 2018-12-18 | 2020-07-31 | Argenx Bvba | Terapia de combinación cd70 |
EP3986403A1 (en) * | 2019-06-20 | 2022-04-27 | Celgene Corporation | Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome |
TW202138388A (zh) * | 2019-12-30 | 2021-10-16 | 美商西根公司 | 以非海藻糖苷化抗-cd70抗體治療癌症之方法 |
IL300996A (en) * | 2020-08-29 | 2023-04-01 | argenx BV | Treatment method for patients with reduced sensitivity to BCL-2 inhibitor |
EP4373486A1 (en) * | 2021-07-21 | 2024-05-29 | Emory University | Bak activators, pharmaceutical compositions, and uses in treating cancer |
TW202319400A (zh) * | 2021-09-02 | 2023-05-16 | 瑞士商赫孚孟拉羅股份公司 | 用於治療aml之抗體 |
WO2023081721A1 (en) * | 2021-11-03 | 2023-05-11 | Board Of Regents, The University Of Texas System | Methods relating to treatment of acute myeloid leukemia |
US11945785B2 (en) | 2021-12-30 | 2024-04-02 | Biomea Fusion, Inc. | Pyrazine compounds as inhibitors of FLT3 |
CN114949230A (zh) * | 2022-06-13 | 2022-08-30 | 厦门大学附属第一医院 | 一种预防和/或治疗急性髓系白血病的联合用药物组合物及其应用 |
CN117771177A (zh) * | 2023-08-02 | 2024-03-29 | 首都医科大学附属北京儿童医院 | 维奈克拉自微乳化释药系统及其制备方法和应用 |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US5573924A (en) | 1992-09-08 | 1996-11-12 | Immunex Corporation | CD27 ligand |
DE19747418C1 (de) | 1997-10-27 | 1999-07-15 | Deutsches Krebsforsch | Inhibitor-Protein des wnt-Signalwegs |
US6500633B1 (en) | 2000-04-26 | 2002-12-31 | Atairgin Technologies, Inc. | Method of detecting carcinomas |
US20030148321A1 (en) | 2001-08-24 | 2003-08-07 | Iris Pecker | Methods and kits for diagnosing and monitoring hematopoietic cancers |
EP1470247A2 (en) | 2001-11-05 | 2004-10-27 | Deutsches Krebsforschungszentrum | Novel genetic markers for leukemias |
US7261892B2 (en) | 2001-11-27 | 2007-08-28 | Celltech R&D Limited | Methods for diagnosis and treatment of epithelial-derived cancers |
WO2003046581A2 (en) | 2001-11-27 | 2003-06-05 | Oxford Glycosciences (Uk) Ltd | Methods for diagnosis and treatment of epithelial-derived cancers,such as colorectal cancers and kidney cancers |
US8404716B2 (en) | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
US8039218B2 (en) | 2002-11-14 | 2011-10-18 | John Wayne Cancer Institute | Detection of cancer cells in body fluids |
US20080025989A1 (en) | 2003-02-20 | 2008-01-31 | Seattle Genetics, Inc. | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
AU2004213053C1 (en) | 2003-02-20 | 2009-07-16 | Seagen Inc. | Anti-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
SG188175A1 (en) | 2004-06-03 | 2013-03-28 | Novimmune Sa | Anti-cd3 antibodies and methods of use thereof |
US8337838B2 (en) | 2004-10-15 | 2012-12-25 | Seattle Genetics, Inc. | Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders |
JP5222559B2 (ja) | 2004-10-15 | 2013-06-26 | シアトル ジェネティックス, インコーポレイテッド | 癌および免疫障害の処置および予防のための抗cd70抗体ならびにその使用 |
US7641903B2 (en) | 2004-10-15 | 2010-01-05 | Seattle Genetics, Inc. | Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders |
CA2605507C (en) | 2005-04-19 | 2016-06-28 | Seattle Genetics, Inc. | Humanized anti-cd70 binding agents and uses thereof |
US20060275844A1 (en) | 2005-04-19 | 2006-12-07 | Linke Steven P | Diagnostic markers of breast cancer treatment and progression and methods of use thereof |
WO2007011856A2 (en) | 2005-07-15 | 2007-01-25 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for differential diagnosis of chronic lymphocytic leukemia |
AU2006294663B2 (en) | 2005-09-26 | 2012-03-22 | Medarex, Inc. | Human monoclonal antibodies to CD70 |
US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
US8409577B2 (en) | 2006-06-12 | 2013-04-02 | Emergent Product Development Seattle, Llc | Single chain multivalent binding proteins with effector function |
EP2055400A1 (en) | 2006-07-24 | 2009-05-06 | Senda Kensetsu Kabushiki Kaisha | Method of descaling metal wire rod and apparatus therefor |
ES2523915T5 (es) | 2006-12-01 | 2022-05-26 | Seagen Inc | Agentes de unión a la diana variantes y usos de los mismos |
AU2007333098A1 (en) | 2006-12-14 | 2008-06-19 | Medarex, Inc. | Human antibodies that bind CD70 and uses thereof |
KR100807069B1 (ko) | 2007-09-21 | 2008-02-25 | 고려대학교 산학협력단 | 암 치료용 의약 조성물 |
EP2217223A2 (en) | 2007-11-05 | 2010-08-18 | Novartis AG | Methods and compositions for measuring wnt activation and for treating wnt-related cancers |
GB2461546B (en) | 2008-07-02 | 2010-07-07 | Argen X Bv | Antigen binding polypeptides |
WO2010014948A1 (en) | 2008-08-01 | 2010-02-04 | The University Of Utah Research Foundation | Methods of treatment using wnt inhibitors |
WO2010019921A2 (en) | 2008-08-15 | 2010-02-18 | The Regents Of The University Of California | Biomarkers for diagnosis and treatment of chronic lymphocytic leukemia |
NZ592338A (en) | 2008-09-26 | 2012-11-30 | Oncomed Pharm Inc | Frizzled-binding agents and uses thereof |
ES2571235T3 (es) | 2009-04-10 | 2016-05-24 | Kyowa Hakko Kirin Co Ltd | Procedimiento para el tratamiento de un tumor sanguíneo que utiliza el anticuerpo anti-TIM-3 |
US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
HUE028259T2 (en) | 2009-08-10 | 2016-12-28 | Samumed Llc | Inhibitors of Wnt signaling signal indazole and their therapeutic use |
WO2011035433A1 (en) | 2009-09-23 | 2011-03-31 | University Health Network | Selected strains on serum-free growth media for proteomics analysis of lung cancer biomarkers |
CN102918059A (zh) | 2009-12-29 | 2013-02-06 | 协和发酵麒麟株式会社 | 抗cd27抗体 |
EP3363499A1 (en) | 2010-06-11 | 2018-08-22 | Kyowa Hakko Kirin Co., Ltd. | Anti-tim-3 antibody |
DK2643322T3 (en) | 2010-11-23 | 2017-12-11 | Abbvie Inc | SALTS AND CRYSTAL FORMS OF AN APOPTOSIS-INducing Agent |
DK2665749T3 (en) | 2011-01-19 | 2016-03-21 | Cantargia Ab | Anti-il1rap antibodies and their use for the treatment of solid tumors |
DK2686347T3 (en) | 2011-03-16 | 2018-06-25 | Argenx Bvba | Antibodies against CD70 |
US8841418B2 (en) | 2011-07-01 | 2014-09-23 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to TIM3 |
MY173865A (en) | 2011-09-22 | 2020-02-25 | Amgen Inc | Cd27l antigen binding proteins |
WO2013093508A2 (en) | 2011-12-22 | 2013-06-27 | Oslo University Hospital Hf | Wnt pathway inhibitors |
SG10201710574UA (en) | 2012-03-15 | 2018-02-27 | Janssen Biotech Inc | Human anti-cd27 antibodies, methods and uses |
JP6194350B2 (ja) | 2012-03-21 | 2017-09-06 | エリテック・ファルマ | 急性骨髄性白血病(aml)の処置のための薬剤 |
WO2013177420A2 (en) | 2012-05-23 | 2013-11-28 | St. Jude Children's Research Hospital | Methods and compositions for the treatment of bcr-abl positive lymphoblastic leukemias |
SG11201408237YA (en) | 2012-06-15 | 2015-01-29 | Curegenix Inc | Compound as wnt signaling inhibitor, composition, and use thereof |
WO2014045101A1 (en) | 2012-09-21 | 2014-03-27 | Cellzome Gmbh | Tetrazolo quinoxaline derivatives as tankyrase inhibitors |
WO2014100772A1 (en) | 2012-12-21 | 2014-06-26 | Cellerant Therapeutics, Inc. | Antibodies that bind membrane-bound il1rap |
SG11201506243XA (en) | 2013-02-14 | 2015-09-29 | Bristol Myers Squibb Co | Tubulysin compounds, methods of making and use |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
EP3116544A4 (en) | 2014-03-11 | 2017-08-23 | The Board of Trustees of the Leland Stanford Junior University | Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies |
US20160200815A1 (en) | 2015-01-05 | 2016-07-14 | Jounce Therapeutics, Inc. | Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof |
TWI717375B (zh) | 2015-07-31 | 2021-02-01 | 德商安美基研究(慕尼黑)公司 | Cd70及cd3抗體構築體 |
WO2017044752A1 (en) | 2015-09-10 | 2017-03-16 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Anti-fibrotic effect of cd70 |
HRP20220436T1 (hr) | 2015-11-03 | 2022-05-27 | Janssen Biotech, Inc. | Protutijela koja se specifično vežu na pd-1 i njihove uporabe |
EA039859B1 (ru) | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
US11001582B2 (en) | 2016-03-10 | 2021-05-11 | Assia Chemical Industries Ltd. | Solid state forms of Venetoclax and processes for preparation of Venetoclax |
WO2017160954A1 (en) * | 2016-03-15 | 2017-09-21 | Seattle Genetics, Inc. | Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors |
JP2019521110A (ja) | 2016-06-09 | 2019-07-25 | ドクター レディズ ラボラトリーズ リミテッド | ベネトクラクスの固体形態およびベネトクラクスの調製のためのプロセス |
US20190225607A1 (en) | 2016-07-06 | 2019-07-25 | Concert Pharmaceuticals, Inc. | Deuterated Venetoclax |
CN107648185A (zh) | 2016-07-25 | 2018-02-02 | 常州爱诺新睿医药技术有限公司 | 一种无定型Venetoclax与药用辅料的固体分散体及其制备方法 |
WO2018029711A2 (en) | 2016-08-12 | 2018-02-15 | Mylan Laboratories Limited | Process for the preparation of venetoclax |
US10800777B2 (en) | 2016-10-14 | 2020-10-13 | Mylan Laboratories Limited | Polymorphic forms of VENCLEXTA |
EP3333167A1 (en) | 2016-12-09 | 2018-06-13 | LEK Pharmaceuticals d.d. | Solid forms of venetoclax |
CZ201769A3 (cs) | 2017-02-06 | 2018-08-15 | Zentiva, K.S. | Pevné formy venetoclaxu |
WO2018157803A1 (zh) | 2017-02-28 | 2018-09-07 | 苏州科睿思制药有限公司 | 维奈妥拉的晶型及其制备方法 |
WO2018167652A1 (en) | 2017-03-13 | 2018-09-20 | Laurus Labs Limited | Process for preparation of amorphous form of venetoclax |
CN107089981A (zh) | 2017-04-24 | 2017-08-25 | 杭州科耀医药科技有限公司 | 一种BCL‑2抑制剂Venetoclax的合成方法 |
GB2567613A (en) * | 2017-06-16 | 2019-04-24 | Argenx Bvba | Treatment for acute myeloid leukaemia |
GB201800649D0 (en) * | 2018-01-16 | 2018-02-28 | Argenx Bvba | CD70 Combination Therapy |
UY38511A (es) | 2018-12-18 | 2020-07-31 | Argenx Bvba | Terapia de combinación cd70 |
-
2019
- 2019-12-17 UY UY0001038511A patent/UY38511A/es not_active Application Discontinuation
- 2019-12-18 FI FIEP19831677.0T patent/FI3890740T3/fi active
- 2019-12-18 KR KR1020217017438A patent/KR20210106428A/ko unknown
- 2019-12-18 MX MX2021007350A patent/MX2021007350A/es unknown
- 2019-12-18 HU HUE19831677A patent/HUE061710T2/hu unknown
- 2019-12-18 BR BR112021011684A patent/BR112021011684A2/pt unknown
- 2019-12-18 IL IL284015A patent/IL284015B1/en unknown
- 2019-12-18 PT PT198316770T patent/PT3890740T/pt unknown
- 2019-12-18 JP JP2021534948A patent/JP2022515077A/ja active Pending
- 2019-12-18 DK DK19831677.0T patent/DK3890740T3/da active
- 2019-12-18 EP EP19831677.0A patent/EP3890740B1/en active Active
- 2019-12-18 LT LTEPPCT/EP2019/085982T patent/LT3890740T/lt unknown
- 2019-12-18 PL PL19831677.0T patent/PL3890740T3/pl unknown
- 2019-12-18 EP EP23151526.3A patent/EP4218761A1/en active Pending
- 2019-12-18 CN CN202211004780.8A patent/CN115920034A/zh active Pending
- 2019-12-18 WO PCT/EP2019/085982 patent/WO2020127503A1/en unknown
- 2019-12-18 CN CN201980082377.7A patent/CN113226317B/zh active Active
- 2019-12-18 ES ES19831677T patent/ES2941638T3/es active Active
- 2019-12-18 SG SG11202105197UA patent/SG11202105197UA/en unknown
- 2019-12-18 CA CA3117282A patent/CA3117282A1/en active Pending
- 2019-12-18 US US16/719,220 patent/US11712468B2/en active Active
- 2019-12-18 AU AU2019409936A patent/AU2019409936A1/en active Pending
-
2023
- 2023-06-14 US US18/334,582 patent/US20240033353A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
HUE061710T2 (hu) | 2023-08-28 |
IL284015A (en) | 2021-08-31 |
PL3890740T3 (pl) | 2023-07-24 |
SG11202105197UA (en) | 2021-07-29 |
BR112021011684A2 (pt) | 2021-11-30 |
TW202038958A (zh) | 2020-11-01 |
EP3890740B1 (en) | 2023-03-01 |
ES2941638T3 (es) | 2023-05-24 |
DK3890740T3 (da) | 2023-05-08 |
WO2020127503A1 (en) | 2020-06-25 |
US11712468B2 (en) | 2023-08-01 |
CN113226317A (zh) | 2021-08-06 |
JP2022515077A (ja) | 2022-02-17 |
EP4218761A1 (en) | 2023-08-02 |
PT3890740T (pt) | 2023-05-15 |
IL284015B1 (en) | 2024-06-01 |
US20200222532A1 (en) | 2020-07-16 |
AU2019409936A1 (en) | 2021-05-27 |
CN115920034A (zh) | 2023-04-07 |
EP3890740A1 (en) | 2021-10-13 |
CN113226317B (zh) | 2022-08-16 |
FI3890740T3 (fi) | 2023-05-24 |
LT3890740T (lt) | 2023-03-27 |
KR20210106428A (ko) | 2021-08-30 |
US20240033353A1 (en) | 2024-02-01 |
MX2021007350A (es) | 2021-09-21 |
CA3117282A1 (en) | 2020-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY38511A (es) | Terapia de combinación cd70 | |
EA202190983A1 (ru) | Новое антитело к с-kit | |
CL2020001575A1 (es) | Anticuerpos anti-trem2 y métodos relacionados. | |
ECSP22057865A (es) | Inhibidores de formas mutantes de egfr | |
CL2018002991A1 (es) | Formulaciones de un inhibidor de lsd1. | |
PE20200012A1 (es) | Anticuerpos mono- y biespecificos que se unen al factor de coagulacion ix y al factor de coagulacion x | |
PE20180480A1 (es) | Anticuerpos de factor xi y metodos de uso | |
PE20210167A1 (es) | Proteinas de union multiespecificas y mejoras con estas | |
CO2021016504A2 (es) | Inhibidores de cdk | |
AR110728A1 (es) | Terapia combinada para el tratamiento del cáncer | |
CU24568B1 (es) | Anticuerpo inhibidor de masp-3 | |
MX2022011750A (es) | Combinaciones farmaceuticas para el tratamiento de cancer. | |
AR062419A1 (es) | Terapia tumoral con un anticuerpo anti- vegf | |
MX2014006241A (es) | Metodos de tratamiento usando un anticuerpo contra interferon gamma. | |
CL2018000377A1 (es) | Mecanismo de resistencia a inhibidores de bromodominio bet | |
PE20160192A1 (es) | Composiciones y metodo para tratar condiciones asociadas con el complemento | |
EA202090061A1 (ru) | Применение антитела против cd70, argx-110, для лечения острого миелоидного лейкоза | |
AR101740A1 (es) | Terapia de combinación y composiciones | |
CO2020013833A2 (es) | Anticuerpo anti-muerte programada-ligando 1 y su uso | |
EA201990567A1 (ru) | Комбинированная терапия с ингибиторами глутаминазы | |
EA202192575A1 (ru) | Соединения dbait в сочетании с ингибиторами киназ для лечения рака | |
MX2022007962A (es) | Anticuerpo anti-lilrb1 y usos del mismo. | |
CY1124688T1 (el) | Θεραπεια πρωτεϊνουριας | |
EA201992315A1 (ru) | Композиции и способы для лечения рака легкого | |
MX2023013912A (es) | Metodos para inhibir ras. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20240610 |